RxDoctor Payments Data

Justin Mastrucci

Family · Fairlawn, OHNPI 1124727888

Payments from drug & device makers

$1,132in general payments, 2019–2025

Across 14 payments — averaging $80.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291
  • AstraZeneca$126
  • Ultragenyx Pharmaceutical Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$123
  • Lilly USA, LLC$109
  • Axsome Therapeutics, Inc.$108
  • plus $250 from 4 others

What the payments were for

  • Food & beverage$1,132100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,132 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$26,020
Medicare patients
216
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$50,972
MounjaroTirzepatide17$24,062
JardianceEmpagliflozin18$22,859
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,294
SymbicortBudesonide/Formoterol Fumarate19$5,034
Albuterol Sulfate HfaAlbuterol Sulfate71$1,778
Atorvastatin Calcium130$1,678
Omeprazole64$1,604
Risedronate Sodium11$1,078
Rosuvastatin Calcium77$1,026
Metoprolol Succinate73$961
Propafenone Hcl12$960
Losartan Potassium90$957
Celecoxib26$743
Levothyroxine Sodium76$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$109$24,06217 claims
AstraZenecaSymbicort$126$5,03419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Fairlawn

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →